Anne H. Schmieder

TL;DR: The potential of combined molecular imaging and drug delivery with targeted nanoparticles to noninvasively define atherosclerotic burden, to deliver effective targeted drug at a fraction of previous levels, and to quantify local response to treatment is illustrated.

TL;DR: Both small molecules based typical blood pool contrast agents and more recently developed novel nanometer sized materials are reviewed focusing on a number of successful molecular imaging examples.

TL;DR: Combining high-resolution MR molecular imaging with drug delivery will facilitate verification and quantification of treatment (ie, rational targeted therapy) and will offer new clinical approaches to many diseases.

TL;DR: A novel molecular imaging agent based on ytterbium designed for use with spectral "multicolor" computed tomography (CT) exhibited excellent signal sensitivity, and the spectral CT technique uniquely discriminates the K-edge signal of Yb from calcium (bones).

TL;DR: As perfluorocarbon nanoparticles have recently entered Phase I clinical study, this review provides a timely focus on the development of this platform technology and its application for angiogenesis-related pathologies.